Share This

Related Topics News -

     
 Detail   |   Print 
     
藥明康德高開15% 美國修改限制中國生物科技企業法案 推遲中斷時間
2024-05-13T  
《大行》大摩降藥明合聯目標價至39元 評級「增持」
2024-04-18T  
《大行報告》建銀國際降藥明合聯目標價至20.9元 前景謹慎樂觀
2024-03-27T  
《大行報告》麥格理降藥明合聯評級至「中性」 削目標價至18元
2024-03-27T  
《公司業績》藥明合聯全年純利2.84億人民幣增82.1% 不派息
2024-03-25T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.